Finally, increasing evidence also suggests that there is a “pathogenic crosstalk” between the immune system and metabolic signaling in sporadic ALS, but more research is needed to assess whether targeting leptin and/or the immune-metabolic axis has therapeutic potential. This evidence concerns the gene LEP and amyotrophic lateral sclerosis.